Back to News & Events

CFB Client Secures $3M Public and Private Investment

November 14, 2017

Codagenix, Inc., a clinical stage, venture and public-sector-funded small business, announced it has secured an additional $3M in funding in support of its live-attenuated Respiratory Syncytial Virus (RSV) vaccine candidate that was developed in collaboration with National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH.

The public funding to Codagenix is via a Phase II SBIR grant for $1.5M to support the pre-clinical manufacturing of the vaccine candidate. The private funding of $1.5M was provided by TopSpin Partners to support a Phase I trial to demonstrate safety and immunogenicity in aged volunteers. The two funding source were not linked; however, both are dedicated to supporting Codagneix’s RSV vaccine through a Phase I trial. Clinical Trial material of Codagenix RSV Vaccine candidate is currently being manufactured with a Phase I targeted for Q3- or Q4-2018.

“Codagenix is an incredible example of a company rooting in our expanding bioecosystem, growing from a startup out of Stony Brook University into a clinical stage company” stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. “The Center for Biotechnology is proud to provide ongoing support for the work they are doing through our various programs including the Applied Research and Development awards and the Long Island Bioscience Hub funding initiatives.

“We are wrapping up a Phase I with our live-attenuated Influenza Vaccine in Q1-2018 and are very much looking forward to adding a second clinical-stage compound to our pipeline with RSV,” stated Codegenix COO J. Robert Coleman. “We are grateful to our investors and partners like the Center for Biotechnology that understand our vision and continually support our development at these early stages. We are demonstrating that our platform provides a rational means to design vaccines against a range targets – yielding candidates suitable for full clinical development.”

Codagenix has raised a total of $10M since 2015 – with its influenza vaccine candidate currently in Phase I and a pre-clinical pipeline that includes Zika, Dengue, and Agricultural targets in addition to RSV.

RSV is a virus that targets newborns and the elderly, with an estimated market size of $2 Billion for a potential RSV vaccine.

About Codagenix Inc.
Codagenix Inc., a biotechnology company on Long Island, New York, is developing live attenuated vaccines using a “disruptive” software-based rational design algorithm that is unlike previous vaccine “platforms”. By leveraging the redundancy in the genetic code (various codons exist at the gene level to encode the same amino acid at the protein level), the Codagenix algorithm re-structures viral genomes into a sub-optimal genetic code. The so-called “deoptimized” viruses have resulted in highly attenuated vaccine strains that are effective at greatly reduced doses, because they present every antigen of the pathogen, while being 100% identical to the target pathogen at the protein level. The Codagenix pipeline of vaccines includes Influenza, respiratory syncytial virus (RSV), Zika, Dengue, foot-and-mouth disease virus (FMDV), pathogenic E. coli, and other pathogens.

Codagenix has also been supported the Center for Biotechnology at Stony brook University which is a New York State Center for Advanced Technology and NIH-designated Research, Evaluation and Commercialization Hub (REACH)

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.





The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development. 





Read more about IAMBIC and their recent funding here.


                    [post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
                    [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-19 10:50:15
                    [post_modified_gmt] => 2024-11-19 15:50:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=4439
                    [menu_order] => 0
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 1417
                    [post_author] => 3
                    [post_date] => 2015-02-19 19:17:30
                    [post_date_gmt] => 2015-02-19 19:17:30
                    [post_content] => Presented by Clean Energy Business Incubator Program



Wednesday, March 11, 2015

Long Island High Tech Incubator

3:30 PM - 5:00 PM: Seminar

5:00 PM - 7:00 PM: Mixer



In most cases for a startup, having patent, trade secret, trademark, and/or copyright protection is the key leverage needed to attract the life-blood investment necessary to sustain and grow the startup to exit. This discussion will address from a startup's perspective how to maintain the maximum potential value of Intellectual Property you may have AND future Intellectual Property that you don't even know about yet!



You will learn about:


    

	
  • Patent, Trademark, Copyright and Trade Secret Basics
    • 

	
  • Common misconceptions about IP, e.g., Patentability and enforcement vs. Freedom-to-Operate
    • 

	
  • Preparing for your pitch and the resultant Due Diligence
    • 

	
  • What steps to take (or not to take) in order to avoid losing your precious IP leverage: Unintentionally forfeiting IP rights,Controlling ownership,And other IP portfolio building strategies
    • 




Speakers: Ray Farrell, founding partner of Carter, DeLuca, Farrell & Schmidt, LLP; Pina Campagna, Patent & Trademark Attorney at Carter, DeLuca, Farrell & Schmidt, LLP.



RSVP to David C Hamilton Director, Business Development, Clean Energy Business Incubator Program (CEBIP): david.hamilton@stonybrook.edu
                    [post_title] => Startup Mission Critical: How to build an IP portfolio investors will want to invest in early and often
                    [post_excerpt] => In most cases for a startup, having patent, trade secret, trademark, and/or copyright protection is the key leverage needed to attract the life-blood investment necessary to sustain and grow the startup to exit.
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => startup-mission-critical-how-to-build-an-ip-portfolio-investors-will-want-to-invest-in-early-and-often
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2016-03-02 18:02:01
                    [post_modified_gmt] => 2016-03-02 18:02:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => http://centerforbiotechnology.org/new/?p=1417
                    [menu_order] => 214
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 3469
                    [post_author] => 3
                    [post_date] => 2020-05-05 08:25:54
                    [post_date_gmt] => 2020-05-05 08:25:54
                    [post_content] => *This list will be updated as opportunities arise. (Updated 7.21.20)

NIH & NIAD Limited Competition Emergency Awards: Shared PPPE Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies

The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”. Rolling deadline - details here: https://grants.nih.gov/grants/guide/pa-files/PAR-20-256.html#_Section_I._Funding



NIH & NIBIB Rapid Acceleration of Diagnostics (RADx) 

Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American. The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Learn more: https://www.poctrn.org/radx

Pfizer COVID-19 Competitive Grant Program 

Pfizer has released a Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis. This competitive grant program from Pfizer Global Medical Grants (GMG) involves a publicly posted RFP that provides details regarding a specific area of interest, sets timelines for review and approval, and uses an internal review process to make final grant decisions. For this RFP, organizations are invited to submit an application addressing the gaps in knowledge and practice of COVID-19 management as outlined here.

Mozilla launches COVID-19 Solutions Fund

Mozilla has created a COVID-19 Solutions Fund as part of the Mozilla Open Source Support Program (MOSS). Through this fund, awards of up to $50,000 each will be provided to open source technology projects which are responding to the COVID-19 pandemic in some way.

As part of the COVID-19 Solutions Fund, applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation)will be accepted. More details here. Application here.

NYS COVID-19 Manufacturing Grants for Masks, Ventilators

The COVID-19 Manufacturing Grants, part of the Jeff Lawrence Innovation Fund, are designed to aid existing New York State small to medium-sized manufacturing companies that can meet prevailing FDA requirements and can quickly accelerate production of personal protective equipment and respiratory care equipment that has been depleted due to the COVID-19 outbreak. Full details here. (Deadline April 17, 2020)

NIBIB announces three COVID-19 Notices of Special Interest

Multiple Notices of Special Interest include administrative supplements and emergency competitive revisions funding for current grantees; SBIR/STTR opportunities; and investigator-initiated research opportunities. Current grantees and new applicants are encouraged to apply immediately. More here.

Fast Grants 

Fast Funding for COVID-19 Science. Scientist at academic institutions currently working on a COVID-19 related project and in need of funding are invited to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. More: fastgrants.org

NIH COVID-Specific Funding Opportunities (Update) 

Multiple Agency NOSI listed here.

National Institute of Allergy and Infectious Diseases: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed) RFA-AI-20-028

Administrative Supplements to Existing NIH Grants and Cooperative Agreements: Funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award. More.

Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements: Funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner. More.

NSF Request for SBIR/STTR Phase I Proposals Addressing COVID-19

Phase I proposals should focus on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations. To apply, you must first develop and submit a Project Pitch at https://seedfund.nsf.gov/apply/. Assuming your pitch is approved, you will be invited by NSF to submit a grant application. More information here.

Department of Defense - Newton Award for Transformative Ideas during the COVID-19 Pandemic

This award will be presented to a single investigator or team of up to two investigators that develops a “transformative idea” to resolve challenges, advance frontiers, and set new paradigms in areas of immense potential benefit to DoD and the nation at large. BRO-20-NEWTON (5/5/20 deadline)

COVID-19 Therapeutics Accelerator

Established by The Gates Foundation and Wellcome, this initiative aims to accelerate and evaluate new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term. The COVID-19 Therapeutics Accelerator will not be conducting a traditional funding call. To learn more about the funding process, or how to invest in the accelerator, contact epidemics@wellcome.ac.uk 

Small Business Assistance Programs

Stony Brook University Small Business Development Center is available to assist business owners trough the abundance of resources available for your particular business/industry and to avoid the most common mistake of incomplete or inaccurate Economic Injury Disaster Assistance Loan applications. Visit their website for more information.

Stony Brook University CEAS Student Opportunity: COVID-19 Innovation Teams

Stony Brook University's College of Engineering and Applied Sciences' Vertically Integrated Project Program is focusing special attention on the urgent needs of the COVID-19 pandemic. Learn more.

Innovate2Ventilate: The CoVent-19 Challenge

The CoVent-19 Challenge invites engineers, innovators, designers, and makers to produce rapidly deployable designs for mechanical ventilators. Launching on April 1, 2020, the deadline for the open-entry round of competition is May 1, 2020. Round 2 of the challenge is an invitation-only competition with a deadline of June 1, 2020. More: coventchallenge.com



COVID-19 Funding Opportunities - Summary via Stony Brook University Research 

The funding opportunities listed here are posted on the Pivot database, grants.gov, NIH Guide for Grants and Contracts, and nsf.gov. Detailed information on NIH funding opportunities and other guidance related to COVID-19 can be found here. Investigators should check eligibility and obtain any necessary approvals before applying.

Stony Brook University Faculty Funding Opportunity 

Stony Brook University Office of the Vice President for Research, together with the Institute for Engineering-Driven Medicine, announce this special initiative COVID-19 seed funding opportunity.

The purpose of this program is to seed research that has a direct connection to the current COVID-19 pandemic.Applications are due April 10. Details about eligibility, award amounts and application process can be found here.



Contacting New York State to offer your COVID-19 Resource: 

Businesses with capabilities relevant to needed medical equipment and supplies email to COVID19supplies@esd.ny.gov.

Businesses interested in selling products to the state should contact Simonida Subotic at 646-522-8477 or covid19supplies@exec.ny.gov.

Businesses interested in receiving state funding to manufacture PPE products should contact Eric Gertler at 212-803-3100 or COVID19supplies@esd.ny.gov.

Indie Bio Coronavirus Initiative 

Indie Bio is seeking up to 8 startups to receive a minimum of $250,000 each to pursue the development of diagnostics, therapeutics, vaccines, disinfection, and other solutions addressing the worldwide problem of emerging infectious diseases. More.

BARDA COVID-19 Funding Opportunities

BARDA BAA (no funding limit) 

Novel Coronavirus EZ-BAA (solicitations for funding up to $750K)

Research Foundation of SUNY COVID-19 Funding Opportunities 

**NEW**  SUNY Research Seed Grant Program RFP #20-03-COVID & Submission form.

Aggregate list of opportunities: https://www.rfsuny.org/about-us/covid-19/covid-19-funding/

Biotechnology Innovation Organization (BIO) Coronavirus Resources

Resource page includes Business Resource Center, Service Provider Directory and Coronoavirus Hub where companies can share what they need and how they can help.

CAD $200K ventilator design challenge for COVID-19 patients 

the Challenge is lead by Code Life.ca and the Montreal General Hospital foundations. The designs are due end of March 2020. The details and rules are posted there, and participants can sign up to begin: https://www.agorize.com/en/challenges/code-life-challenge/

OTHER CHALLENGES

Business Incubator Association of New York State - Innovate to Ventilate 

Hauppauge Industrial Association of Long Island (HIA-LI) Pivot to PPE

RESOURCES

COVID-19 Open Research Dataset (CORD-19)
Ginkgo commits $25M of free access to platform for partner COVID-19 projects

 
                    [post_title] => COVID-19 Funding and Resource Opportunities
                    [post_excerpt] => An aggregate list of COVID-19 related funding opportunities and technology and business related resources. This list will be updated as opportunities arise. 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => covid-19-resources
                    [to_ping] => 
                    [pinged] => 
https://indiebio.co/indiebio-covid-response/
                    [post_modified] => 2020-07-21 13:20:53
                    [post_modified_gmt] => 2020-07-21 13:20:53
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3469
                    [menu_order] => 71
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 3301
                    [post_author] => 3
                    [post_date] => 2019-07-22 13:14:41
                    [post_date_gmt] => 2019-07-22 13:14:41
                    [post_content] => The NIH and CDC have released the annual SBIR Contract Proposal Solicitation (PHS 2020-1), with a submission date of October 23, 2019, 5:00 PM EDT. Please follow the directions in the solicitation very carefully. You must respond exactly to a topic in the solicitation.

A pre-proposal conference, via webinar, will take place on August 7 at 1:00 PM EDT. This informational webinar will discuss the PHS 2020-1 solicitation, electronic contract proposal submission (eCPS) website, clinical trials, and topics.

Please register for HHS SBIR PHS 2020-1 Contract Webinar in advance, here:
https://attendee.gotowebinar.com/register/7505039171902241027

(After registering, you will receive a confirmation email containing information about joining the webinar.)

The following Institutes/Centers have issued research topics in the PHS 2020-1 Solicitation:

National Institutes of Health (NIH)

    
 	
  • National Center for Advancing Translational Sciences (NCATS)
    • 
 	
  • National Cancer Institute (NCI)
    • 
 	
  • National Heart, Lung and Blood Institute (NHLBI)
    • 
 	
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)
    • 
 	
  • National Institute of Allergy and Infectious Diseases (NIAID)
    • 


Centers for Disease Control and Prevention (CDC)

    
 	
  • National Center for Chronic Disease and Health Promotion (NCCDPHP)
    • 
 	
  • National Center for Environmental Health (NCEH)
    • 
 	
  • National Center for Emerging Zoonotic and Infectious Diseases (NCEZID)
    • 
 	
  • National Center for Immunization and Respiratory Diseases (NCIRD)
    • 


Submission Process: There is an electronic submission process for all proposals. Applicants must use the Contract Proposal Submission (eCPS) website to submit their proposal. No other method of proposal submission is permitted. Instructions for electronic submission are provided in the solicitation.

Please check NOT-OD-19-121 for topics, contracting officer contact information and other details. You can also find the SBIR contract solicitation link on theFunding page and FedBizOpps.

Those interested in the PHS small business research GRANT programs, where investigator-initiated research ideas are encouraged, should use the Omnibus SBIR and STTR solicitations. You can find solicitation links on the Funding page. To understand better the differences between grants and contracts, view the Apply page.
                    [post_title] => NIH/CDC SBIR Contract Solicitation Now Available
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => open
                    [ping_status] => open
                    [post_password] => 
                    [post_name] => nihcdc-sbir-contract-solicitation-now-available
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2019-07-22 13:14:41
                    [post_modified_gmt] => 2019-07-22 13:14:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://centerforbiotechnology.org/?p=3301
                    [menu_order] => 92
                    [post_type] => post
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [post_count] => 4
    [current_post] => -1
    [before_loop] => 1
    [in_the_loop] => 
    [post] => WP_Post Object
        (
            [ID] => 4439
            [post_author] => 3
            [post_date] => 2024-07-30 15:29:07
            [post_date_gmt] => 2024-07-30 19:29:07
            [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.





The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development. 





Read more about IAMBIC and their recent funding here.


            [post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant
            [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. 
            [post_status] => publish
            [comment_status] => closed
            [ping_status] => closed
            [post_password] => 
            [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant
            [to_ping] => 
            [pinged] => 
            [post_modified] => 2024-11-19 10:50:15
            [post_modified_gmt] => 2024-11-19 15:50:15
            [post_content_filtered] => 
            [post_parent] => 0
            [guid] => https://centerforbiotechnology.org/?p=4439
            [menu_order] => 0
            [post_type] => post
            [post_mime_type] => 
            [comment_count] => 0
            [filter] => raw
        )

    [comment_count] => 0
    [current_comment] => -1
    [found_posts] => 261
    [max_num_pages] => 87
    [max_num_comment_pages] => 0
    [is_single] => 
    [is_preview] => 
    [is_page] => 
    [is_archive] => 
    [is_date] => 
    [is_year] => 
    [is_month] => 
    [is_day] => 
    [is_time] => 
    [is_author] => 
    [is_category] => 
    [is_tag] => 
    [is_tax] => 
    [is_search] => 
    [is_feed] => 
    [is_comment_feed] => 
    [is_trackback] => 
    [is_home] => 1
    [is_privacy_policy] => 
    [is_404] => 
    [is_embed] => 
    [is_paged] => 
    [is_admin] => 
    [is_attachment] => 
    [is_singular] => 
    [is_robots] => 
    [is_favicon] => 
    [is_posts_page] => 
    [is_post_type_archive] => 
    [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0
    [query_vars_changed:WP_Query:private] => 
    [thumbnails_cached] => 
    [allow_query_attachment_by_filename:protected] => 
    [stopwords:WP_Query:private] => 
    [compat_fields:WP_Query:private] => Array
        (
            [0] => query_vars_hash
            [1] => query_vars_changed
        )

    [compat_methods:WP_Query:private] => Array
        (
            [0] => init_query_flags
            [1] => parse_tax_query
        )

)

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

July 30, 2024

More Information

Startup Mission Critical: How to build an IP portfolio investors will want to invest in early and often

February 19, 2015

More Information

COVID-19 Funding and Resource Opportunities

May 5, 2020

More Information

NIH/CDC SBIR Contract Solicitation Now Available

July 22, 2019

More Information